TY - JOUR T1 - Biologic DMARD May Be Insufficient to Inhibit CCL20 Pathway in Rheumatoid Arthritis JF - The Journal of Rheumatology JO - J Rheumatol SP - 2430 LP - 2430 DO - 10.3899/jrheum.100551 VL - 37 IS - 11 AU - RUI-XUE LENG AU - DONG-QING YE Y1 - 2010/11/01 UR - http://www.jrheum.org/content/37/11/2430.1.abstract N2 - To the Editor:Kawashiri, et al recently reported that biologic disease-modifying antirheumatic drugs (DMARD; i.e., infliximab, etanercept, and tocilizumab) may have therapeutic efficacy by inhibiting CCL20 production in rheumatoid synovium1. Indeed, serum CCL20 concentration in patients with rheumatoid arthritis (RA) was clearly decreased by treatment with biologic DMARD. As well, DMARD also can inhibit the production … Address correspondence to Prof. D-Q. Ye; E-mail: ydq{at}ahmu.edu.cn ER -